Resources
63 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 10/7/2019 (updated 3/25/2024)
An Introduction to Harm Reduction Webinar Presentation and Materials
Posted 10/7/2019 (updated 3/25/2024)
Meeting the Workforce Challenges of the Opioid Crisis in Rural America Webinar Presentation and Materials
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.
Posted 3/14/2022 (updated 3/27/2024)
Substance use and its progression to impairment, loss of control, and development of substance use disorders is a significant problem for adolescents and young adults. This presentation will provide an overview of developmentally-informed approaches to engaging youth and their families in treatment.
Learning Objectives:
Recognize motivational approaches to working with substance involved youth
Identify approaches to engaging families of substance involved youth
Speaker: Marc Fishman, MD
Posted 7/27/2022 (updated 3/27/2024)
This presentation will focus on the relationship between trauma and substance use as it relates to treatment for women, as well as a discussion of impactful trauma-informed and gender-responsive interventions. The evidence-based interventions will be based on Seeking Safety and Finding Your Best Self models, both of which are present-focused and easily implemented in any treatment setting.
Posted 8/23/2022 (updated 3/27/2024)
This observational study of 719 612 pharmacy claims data shows that OOP costs of naloxone grew substantially beginning in 2016. However, OOP costs did not increase for all patients and all brands of naloxone but primarily for uninsured patients and for the Evzio brand. The findings suggest that the OOP cost of naloxone has been an increasingly substantial barrier to naloxone access for uninsured patients, a population that constitutes nearly one-fifth of adults with opioid use disorder.
Posted 3/21/2023 (updated 3/27/2024)
Training materials A Stimulating Talk
Posted 3/7/2023 (updated 3/27/2024)
Training material Pre-Addiction: Research Needed to Evaluate its Public Health Value
Posted 3/29/2023 (updated 3/27/2024)
The University of Rochester Medicine Recovery Center of Excellence is offering free trainings to provide guidance on evidence-based strategies to work through resistance and encourage help-seeking behavior. Cognitive Behavioral Therapy for Treatment Seeking (CBT-TS) is an evidence-based technique to encourage help seeking among those in need.
Posted 4/4/2023 (updated 3/27/2024)
The U.S. Food and Drug Administration (FDA) announced that the makers of Narcan, an opioid overdose treatment, have the agency’s approval to make the drug widely available over the counter (OTC). Narcan is the brand name of the drug naloxone, a fast-acting overdose reversal. Until now, availability varied by state – typically restricted to licensed health care providers, approved opioid overdose programs, and first responders. This is an important consideration for rural counties given that research shows that these areas are nearly three times more likely than metropolitan counties to be a low-dispensing county for naloxone.